Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model

Journal of Nuclear Medicine

Volumn 50, Issue 2, 2009, Pages 296-302

  Kletting, Peter ^a   Bunjes, Donald ^a   Reske, Sven N ^a   Glatting, Gerhard ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Anti CD45 antibody; PBPK model; Preload; Radioimmunotherapy

Indexed keywords

CD45 ANTIBODY; CD45 ANTIGEN; INDIUM 111; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD; BLOOD FLOW; BLOOD SAMPLING; BONE MARROW; CLINICAL ARTICLE; DRUG BINDING; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG RETENTION; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN TISSUE; LIVER; LYMPH NODE; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SPLEEN;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; BAYES THEOREM; BONE MARROW; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RADIOIMMUNOTHERAPY; SPLEEN; TISSUE DISTRIBUTION;

EID: 59249089861     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054189     Document Type: Article

References (38)

1. Dearling JL, Pedley RB. Technological advances in radioimmunotherapy. Clin Oncol (R Coll Radiol). 2007;19:457-469.
2. Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55:5908s-5910s.
3. Jurcic JG. Immunotherapy for acute myeloid leukemia. Curr Oncol Rep. 2005;7:339-349.
4. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98:565-572.
5. 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130:604-613.
6. Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med. 2001;28:807-815.
7. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
8. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184-2191.
9. Glatting G, Müller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med. 2006;47:1335-1341.
10. Abutalib SA, Tallman MS. Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr Pharm Biotechnol. 2006;7:343-369.
11. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-834.
12. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46:115S-127S.
13. Nemecek ER, Hamlin DK, Fisher D, et al. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a non human primate model. Clin Cancer Res. 2005;11:787-794.
14. Knox SJ, Goris M, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
15. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85:1122-1131.
16. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood. 2002;100:318-326.
17. Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm. 1995;23:217-229.
18. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55:4611-4622.
19. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet. 2003;42:883-908.
20. Ferl GZ, Wu AM, DiStefano JJ III. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33:1640-1652.
21. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ III. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther. 2006;5:1550-1558.
22. Green AJ, Johnson CJ, Adamson KL, Begent RH. Mathematical model of antibody targeting: important parameters defined using clinical data. Phys Med Biol. 2001;46:1679-1693.
23. Glatting G, Landmann M, Kull T, et al. Internal radionuclide therapy: the UlmDos software for treatment planning. Med Phys. 2005;32:2399-2405.
24. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484-492.
25. Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood. 1991;78:1864-1874.
26. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res. 1992;52:1228-1234.
27. 111In-labeled monoclonal antibody in humans. Cancer Res. 1987;47:3328-3336.
28. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74:163-219.
29. Montesano R, Nicolescu P. Fenestrations in endothelium of rat liver sinusoids revisited by freeze-fracture. Anat Rec. 1978;190:861-887.
30. Leggett RW, Williams LR. A proposed blood circulation model for reference man. Health Phys. 1995;69:187-201.
31. Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys. 2007;34:4285-4292.
32. Ong GL, Mattes MJ. Re-evaluation of the concept of functional affinity as applied to bivalent antibody binding to cell surface antigens. Mol Immunol. 1993;30:1455-1462.
33. Thomas GD, Chappell MJ, Dykes PW, et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989;49:3290-3296.
34. Iversen PO, Thing-Mortensen B, Nicolaysen G, Benestad HB. Decreased blood flow to rat bone marrow, bone, spleen, and liver in acute leukemia. Leuk Res. 1993;17:663-668.
35. 13N-PET. Med Phys. 1999;26:616-621.
36. Gopalakrishnan PV, Karush F. Antibody affinity. VII. Multivalent interaction of anti-lactoside antibody. J Immunol. 1974;113:769-778.
37. Jurcic J-G, Larson S-M, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
38. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310-2314.